In a small Japanese cohort of patients with JDM, muscle weakness was absent in 40% of anti-MDA5 patients and 44% of anti-TIF1-γ at presentation; however, all but one patient with anti-MDA5 autoantibodies developed muscle involvement during follow-up [8]. This evidence concerns the gene IFIH1 and juvenile dermatomyositis.